A Phase 3 interventional study of Lisdexamfetamine dimesylate and Placebo in Binge Eating Disorder, sponsored by Shire. Completed at 53 sites in 5 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-14.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.
Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 7th largest by enrollment of the 112 interventional ones that give a count, is one of 4 that started in 2014, is one of 15 in phase 3, and was the 35th registered.
233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.
Browse Binge-Eating Disorder studies →20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:
Lindner Center of HOPE · Sites in United States
Ages up to 18
Trustees of Dartmouth College · Sites in United States
Ages 18–70
University of Kansas · Sites in United States
Ages 18–65
University of Oklahoma · Sites in United States
Ages 18–120
Milton S. Hershey Medical Center · Sites in United States
Ages 12–26
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 27 · Phase 3 25 · Phase 4 3
First in 1994; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 418 is above the median of 77 across 190 interventional studies indexed under Binge-Eating Disorder.
Median enrollment 67 across the 112 interventional studies, 224 across the 8 observational. Of the 89 that completed or were terminated, 34 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 122 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
Takeda has 6 studies filed under Binge-Eating Disorder — fewer than ten, so there is no comparison to draw.
12 of the studies in Binge-Eating Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413433Phase 3Axsome Therapeutics, Inc.Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | 2026-12 |
| NCT06858774Icahn School of Medicine at Mount SinaiUse of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder | 2026-11 |
| NCT06485687Ali RezaiLow Intensity Focused Ultrasound for Binge Eating Disorder | 2026-12-31 |
| NCT05664516Massachusetts General HospitalA Study of the Effects of Oxytocin in Adults With Binge-eating Disorder | 2027-01 |
| NCT03393039University of California, San DiegoEffects of Negative Affect in Individuals With Binge Eating Episodes | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 122 studies in Binge-Eating Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate maintenance of efficacy based on time to relapse between SPD489 (50 or 70mg) and placebo, as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by clinical interview based on subject diary and Clinical Global Impression - Severity (CGI-S) scores for patients who responded to SPD489 by the end of the Open-label Treatment Phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject meets the following criteria for a diagnosis of BED:
Exclusion Criteria:
Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
Drug: Lisdexamfetamine dimesylate
Administer one capsule orally daily at approximately 7:00 AM.
Other: Placebo
SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
Also known as: SPD489, LDX
Placebo capsule once per day (double-blind period)
Time to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal Period
Relapse status was assessed during the double-blind treatment phase and was defined as having 2 or more binge days per week for 2 consecutive weeks (14 consecutive days) prior to any visit and having an increase in Clinical Global Impressions-Severity (CGI-S) score of 2 or more points compared to the randomized-withdrawal baseline (date of relapse - date of randomization). Binge eating information was captured via a self-report paper diary. The binge diary captured the number of binges per day, total hours per day spent binging, type of binge (at mealtime or at another time other than mealtime), and a description of the binge (amounts and types of foods). Binge frequency was reviewed by the clinician with the subject to confirm reported binge episodes per day. The CGI-S was performed to rate the severity of a subject's condition using a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Change From Randomized-Withdrawal Baseline in The Number of Binge- Eating Days Per Week During The Randomized-withdrawal Period
A binge day was defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on subject binge diary. Binge eating information was captured via a self-report paper diary. The binge diary captured the number of binges per day, total hours per day spent binging, type of binge (at mealtime or at another time other than mealtime), and a description of the binge (amounts and types of foods). Binge frequency was reviewed by the clinician with the subject to confirm reported binge episodes per day. A negative change from Baseline indicates that binge-related behavior decreased. The randomized -withdrawal-baseline was defined as the weekly average number of binge days for the 14 days prior to the Randomization Visit (Visit 8).
Time frame: Randomized--withdrawal baseline (Visit 8; 12 weeks after start of open- label treatment [Week 12]), Visit 21 (26 weeks after randomization [Week 38])
Percent of Participants Within Each Category of The Clinical Global Impression-Severity of Illness (CGI-S) Scale at Endpoint of The Randomized-withdrawal Period
The CGI-S permits a global evaluation of a subject's condition and severity of symptoms. The CGI-S was performed to rate the severity of a subject's condition based on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Change From Randomized-Withdrawal Baseline in The Total Score of The Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) During The Randomized-withdrawal Period
The Y-BOCS-BE measures the obsession of binge eating thoughts and compulsiveness of binge eating behaviors. The scale is a clinician rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). The scale includes questions regarding the amount of time spent on obsessions, impairment or distress experienced, and resistance and control over these thoughts. The same types of questions were asked about compulsions (ie, time spent, interference, etc.).Total scores range from 0 to 40. A total score of 0-7 is sub-clinical, 8-15 is mild, 16-23 is moderate, 24-31 is severe, and 32-40 is extreme. A decrease from baseline in Y-BOCS-BE Total Score represents an improvement in obsession with binge-eating thoughts or compulsiveness of binge-eating behaviors.
Time frame: Randomized-withdrawal baseline (Visit 8; 12 weeks after start of open-label treatment [Week 12]), Visit 21 (26 weeks after randomization [Week 38])
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Mobility at Endpoint of The Open-label Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5--Dimension 5--Level Self--Report Questionnaire (EQ--5D--5L) For Mobility at Endpoint of The Randomized-withdrawal Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care at Endpoint of The Open-label Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care at Endpoint of The Randomized-withdrawal Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities at Endpoint of The Open-label Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities at Endpoint of The Randomized-withdrawal Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort at Endpoint of The Open-label Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort at Endpoint of The Randomized-withdrawal Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety And Depression at Endpoint of The Open-label Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety And Depression at Endpoint of The Randomized-withdrawal Period
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Number of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS) at Endpoint of The Open-label Period
The C-SSRS is a semistructured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.
Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12])
Number of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS) at Endpoint of The Randomized-withdrawal Period
The C-SSRS is a semistructured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Total Scores For The Amphetamine Cessation Symptom Assessment (ACSA) Scale During Follow-up
The ACSA was used in this study to assess potential withdrawal symptoms associated with chronic use of SPD489. The ACSA is a self-completed scale used to assess withdrawal symptoms. The scale has 16 symptom items rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The ACSA total score ranges from 0-64, where a higher score indicates greater withdrawal symptom severity.
Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination) and Visit 22 (7 days post last dose)
| Milestone | SPD489 (Open-label Period) | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|---|
| Started | 418 | 0 | 0 |
| Completed | 275 | 0 | 0 |
| Not completed | 143 | 0 | 0 |
| Withdrew: Failure to meet randomization criteria | 48 | 0 | 0 |
| Withdrew: Withdrawal by subject | 29 | 0 | 0 |
| Withdrew: Adverse event | 22 | 0 | 0 |
| Withdrew: Lost to follow-up | 20 | 0 | 0 |
| Withdrew: Protocol violation | 10 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Other | 13 | 0 | 0 |
| Milestone | SPD489 (Open-label Period) | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|---|
| Started | 0 | 138 | 137 |
| Completed | 0 | 50 | 102 |
| Not completed | 0 | 88 | 35 |
| Withdrew: Withdrawal by subject | 0 | 25 | 9 |
| Withdrew: Lost to follow-up | 0 | 13 | 6 |
| Withdrew: Adverse event | 0 | 0 | 6 |
| Withdrew: Relapse criteria met | 0 | 40 | 5 |
| Withdrew: Protocol violation | 0 | 1 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 2 |
| Withdrew: Other | 0 | 9 | 5 |
Relapse status was assessed during the double-blind treatment phase and was defined as having 2 or more binge days per week for 2 consecutive weeks (14 consecutive days) prior to any visit and having an increase in Clinical Global Impressions-Severity (CGI-S) score of 2 or more points compared to the randomized-withdrawal baseline (date of relapse - date of randomization). Binge eating information was captured via a self-report paper diary. The binge diary captured the number of binges per day, total hours per day spent binging, type of binge (at mealtime or at another time other than mealtime), and a description of the binge (amounts and types of foods). Binge frequency was reviewed by the clinician with the subject to confirm reported binge episodes per day. The CGI-S was performed to rate the severity of a subject's condition using a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).
| days | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| Time to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal Period | NA (55.0 to NA) | NA (NA to NA) |
A binge day was defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on subject binge diary. Binge eating information was captured via a self-report paper diary. The binge diary captured the number of binges per day, total hours per day spent binging, type of binge (at mealtime or at another time other than mealtime), and a description of the binge (amounts and types of foods). Binge frequency was reviewed by the clinician with the subject to confirm reported binge episodes per day. A negative change from Baseline indicates that binge-related behavior decreased. The randomized -withdrawal-baseline was defined as the weekly average number of binge days for the 14 days prior to the Randomization Visit (Visit 8).
| days | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized--Withdrawal Period) |
|---|---|---|
| Change From Randomized-Withdrawal Baseline in The Number of Binge- Eating Days Per Week During The Randomized-withdrawal Period | 0.63 ± 0.076 | 0.02 ± 0.061 |
The CGI-S permits a global evaluation of a subject's condition and severity of symptoms. The CGI-S was performed to rate the severity of a subject's condition based on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).
| percentage of participants | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| Normal, Not at All Ill | 45.0 | 81.6 |
| Borderline Mentally Ill | 10.7 | 11.8 |
| Mildly Ill | 14.5 | 2.2 |
| Moderately Ill | 22.1 | 2.2 |
| Markedly Ill | 6.9 | 2.2 |
| Severely Ill | 0.0 | 0.0 |
| Among the Most Extremely Ill | 0.8 | 0.0 |
The Y-BOCS-BE measures the obsession of binge eating thoughts and compulsiveness of binge eating behaviors. The scale is a clinician rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). The scale includes questions regarding the amount of time spent on obsessions, impairment or distress experienced, and resistance and control over these thoughts. The same types of questions were asked about compulsions (ie, time spent, interference, etc.).Total scores range from 0 to 40. A total score of 0-7 is sub-clinical, 8-15 is mild, 16-23 is moderate, 24-31 is severe, and 32-40 is extreme. A decrease from baseline in Y-BOCS-BE Total Score represents an improvement in obsession with binge-eating thoughts or compulsiveness of binge-eating behaviors.
| units on a scale | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| Change From Randomized-Withdrawal Baseline in The Total Score of The Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) During The Randomized-withdrawal Period | 5.5 ± 0.66 | -0.0 ± 0.52 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Open-label Safety Population |
|---|---|
| I have no problems in walking about | 87.9 |
| I have slight problems in walking about | 9.8 |
| Moderate problems in walking about | 1.5 |
| I have severe problems in walking about | 0.8 |
| I am unable to walk about | 0 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| I have no problems in walking about | 83.6 | 91.3 |
| I have slight problems in walking about | 14.7 | 6.3 |
| Moderate problems in walking about | 1.7 | 1.6 |
| I have severe problems in walking about | 0.0 | 0.8 |
| I am unable to walk about | 0.0 | 0.0 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Open-label Safety Population |
|---|---|
| I have no problems washing or dressing myself | 98.7 |
| I have slight problems washing or dressing myself | 0.8 |
| Moderate problems washing or dressing myself | 0.3 |
| I have severe problems washing or dressing myself | 0.3 |
| I am unable to wash or dress myself | 0 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| I have no problems washing or dressing myself | 98.3 | 98.4 |
| I have slight problems washing or dressing myself | 0.9 | 0.8 |
| Moderate problems washing or dressing myself | 0.9 | 0.8 |
| I have severe problems washing or dressing myself | 0.0 | 0.0 |
| I am unable to wash or dress myself | 0.0 | 0.0 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Open-label Safety Population |
|---|---|
| I have no problems doing my usual activities | 88.9 |
| I have slight problems doing my usual activities | 8.1 |
| Moderate problems doing my usual activities | 2.3 |
| I have severe problems doing my usual activities | 0.8 |
| I am unable to do my usual activities | 0 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| I have no problems doing my usual activities | 79.3 | 86.6 |
| I have slight problems doing my usual activities | 16.4 | 11.0 |
| Moderate problems doing my usual activities | 2.6 | 0.8 |
| I have severe problems doing my usual activities | 0.0 | 1.6 |
| I am unable to do my usual activities | 1.7 | 0.0 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Open-label Safety Population |
|---|---|
| I have no pain or discomfort | 72.3 |
| I have slight pain or discomfort | 20.9 |
| Moderate pain or discomfort | 5.3 |
| I have severe pain or discomfort | 1.3 |
| I have extreme pain or discomfort | 0.3 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| I have no pain or discomfort | 75.0 | 71.7 |
| I have slight pain or discomfort | 16.4 | 18.1 |
| Moderate pain or discomfort | 8.6 | 8.7 |
| I have severe pain or discomfort | 0.0 | 0.0 |
| I have extreme pain or discomfort | 0.0 | 1.6 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Open-label Safety Population |
|---|---|
| I am not anxious or depressed | 80.9 |
| I am slightly anxious or depressed | 15.6 |
| Moderately anxious or depressed | 2.3 |
| I am severely anxious or depressed | 1.0 |
| I am extremely anxious or depressed | 0.3 |
The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.
| percentage of participants | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| I am not anxious or depressed | 66.4 | 79.5 |
| I am slightly anxious or depressed | 26.7 | 15.7 |
| Moderately anxious or depressed | 4.3 | 3.1 |
| I am severely anxious or depressed | 2.6 | 0.8 |
| I am extremely anxious or depressed | 0.0 | 0.8 |
The C-SSRS is a semistructured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.
| participants | Open-label Safety Population |
|---|---|
| Suicidal Behavior | 0 |
| Active Suicidal Ideation | 0 |
| Non-Suicidal Self-Injurious Behavior | 2 |
The C-SSRS is a semistructured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.
| participants | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| Suicidal Behavior | 0 | 0 |
| Active Suicidal Ideation | 0 | 0 |
| Non-Suicidal Self-Injurious Behavior | 0 | 1 |
The ACSA was used in this study to assess potential withdrawal symptoms associated with chronic use of SPD489. The ACSA is a self-completed scale used to assess withdrawal symptoms. The scale has 16 symptom items rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The ACSA total score ranges from 0-64, where a higher score indicates greater withdrawal symptom severity.
| units on a scale | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|
| Visit 21, n=88, 94 | 7.6 ± 8.33 | 4.9 ± 7.81 |
| Visit 22, n=75, 78 | 4.6 ± 5.84 | 5.3 ± 7.98 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPD489 (Open-label Period) | — | 3/411 (0.7%) | 303/411 (73.7%) |
| Placebo (Randomized-withdrawal Period) | — | 0/134 (0%) | 45/134 (33.6%) |
| SPD489 (Randomized-withdrawal Period) | — | 2/136 (1.5%) | 59/136 (43.4%) |
| Event | SPD489 (Open-label Period) | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|---|
| Nerve Root CompressionNervous system disorders | 0/411 | 0/134 | 1/136 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/411 | 0/134 | 1/136 |
| Congenital Anomaly in OffspringCongenital, familial and genetic disorders | 1/411 | 0/134 | 0/136 |
| PneumoniaInfections and infestations | 1/411 | 0/134 | 0/136 |
| ConvulsionNervous system disorders | 1/411 | 0/134 | 0/136 |
| Event | SPD489 (Open-label Period) | Placebo (Randomized-withdrawal Period) | SPD489 (Randomized-withdrawal Period) |
|---|---|---|---|
| Dry mouthGastrointestinal disorders | 139/411 | 2/134 | 7/136 |
| HeadacheNervous system disorders | 66/411 | 9/134 | 12/136 |
| InsomniaPsychiatric disorders | 46/411 | 2/134 | 1/136 |
| NasopharyngitisInfections and infestations | 20/411 | 9/134 | 13/136 |
| Decreased appetiteMetabolism and nutrition disorders | 38/411 | 0/134 | 0/136 |
| NauseaGastrointestinal disorders | 35/411 | 3/134 | 6/136 |
| Upper respiratory tract infectionInfections and infestations | 11/411 | 5/134 | 11/136 |
| AnxietyPsychiatric disorders | 29/411 | 2/134 | 2/136 |
| ConstipationGastrointestinal disorders | 28/411 | 1/134 | 4/136 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 23/411 | 0/134 | 3/136 |
The Open-label Safety Population (OSP) was defined as all participants who had taken at least 1 dose of SPD489 in the open-label period and who had a post-baseline safety assessment. Seven participants were enrolled but not treated and thus not included in the OSP.
| Age, Continuous(years) | Open-label Safety Population |
|---|---|
| Mean | 38.3 ± 10.40 |
| Age, Customized(Participants) | Open-label Safety Population |
|---|---|
| < 40 years of age | 217 |
| >/= 40 years of age | 194 |
| Sex: Female, Male(Participants) | Open-label Safety Population |
|---|---|
| Female | 358 |
| Male | 53 |
Ran from Jan 2014 to primary completion in Apr 2015, 14 months.
Results were first posted in Apr 2016, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine